Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma

The replacement of bleomycin with the immune drug conjugate brentuximab vedotin in the first-line chemotherapy regimen for advanced Hodgkin’s lymphoma prolonged both progression-free and overall survival.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 387; no. 4; pp. 310 - 320
Main Authors Ansell, Stephen M., Radford, John, Connors, Joseph M., Długosz-Danecka, Monika, Kim, Won-Seog, Gallamini, Andrea, Ramchandren, Radhakrishnan, Friedberg, Jonathan W., Advani, Ranjana, Hutchings, Martin, Evens, Andrew M., Smolewski, Piotr, Savage, Kerry J., Bartlett, Nancy L., Eom, Hyeon-Seok, Abramson, Jeremy S., Dong, Cassie, Campana, Frank, Fenton, Keenan, Puhlmann, Markus, Straus, David J.
Format Journal Article
LanguageEnglish
Published Boston Massachusetts Medical Society 28.07.2022
Subjects
Bleomycin
CD30 antigen
Chemotherapy
Clinical outcomes
Colony-stimulating factor
Dacarbazine
Doxorubicin
Granulocyte colony-stimulating factor
Hematology
Immunotherapy
Leukemia
Leukocytes (granulocytic)
Lymphoma
Medical prognosis
Monoclonal antibodies
Neutropenia
Oncology
Patients
Peripheral neuropathy
Prophylaxis
Survival
Survival analysis
Targeted cancer therapy
Transplantation
Treatments in Oncology
Vinblastine
Online AccessGet full text

Cover

More Information
Summary:The replacement of bleomycin with the immune drug conjugate brentuximab vedotin in the first-line chemotherapy regimen for advanced Hodgkin’s lymphoma prolonged both progression-free and overall survival.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2206125